TM Owner Teva Pharmaceuticals
Oxaliplatin Injection 100mg/20ml Vial
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Oxaliplatin Injection 100 mg/20 mL (5 mg/mL) contains oxaliplatin, a platinum-based chemotherapy medicine.
- In the United States and the European Union it is approved, always in combination with infusional fluorouracil and leucovorin (the FOLFOX regimen), for the adjuvant treatment of stage III colon cancer after complete surgical removal of the tumour, and for treatment of advanced or metastatic colorectal cancer in adults.
- It is not approved as a single agent and is not interchangeable with other platinum drugs such as cisplatin or carboplatin.
- Oxaliplatin is given only as an intravenous infusion in a hospital or specialist oncology clinic, prepared and administered by trained oncology staff — it is never taken home or self-administered, and different manufacturers' generic oxaliplatin injection products, including this one, share the same core FDA-approved prescribing information and boxed warning.
Side Effects
- Oxaliplatin carries a boxed warning: serious and sometimes fatal hypersensitivity reactions, including anaphylaxis, can occur within minutes of any infusion, at any cycle, so patients are monitored closely during and after each dose.
- Very common reactions (affecting more than 1 in 10 people) include peripheral sensory neuropathy — tingling, numbness or cold-triggered discomfort in the hands, feet, jaw or throat — along with low blood counts (neutropenia, thrombocytopenia, anaemia), nausea, vomiting, diarrhoea, fatigue, and mouth soreness.
- Serious reactions needing urgent medical attention include signs of a severe allergic reaction (facial swelling, breathing difficulty, widespread rash), unexplained bleeding or bruising, fever suggesting infection, severe or persistent diarrhoea, sudden breathlessness, and irregular heartbeat.
- Report new or worsening numbness promptly, especially if it starts interfering with daily tasks like buttoning clothes, and seek immediate help for any reaction during or shortly after an infusion.
Precautions & Warnings
- Oxaliplatin is for intravenous infusion only, given over about two hours, and must never be given by any other route.
- It is contraindicated in anyone with known hypersensitivity to oxaliplatin or other platinum compounds.
- Liver function tests are checked before treatment starts and before every cycle; unexplained abnormal results or signs of portal hypertension should be investigated further.
- The dose is reduced in severe kidney impairment (creatinine clearance under 30 mL/min).
- Oxaliplatin can harm a developing baby, so effective contraception is required during treatment and for 9 months afterwards in women and 6 months afterwards in men, and breastfeeding must stop during treatment and for 3 months after the final dose.
- Avoid applying ice to the mouth or skin around the time of infusion, since cold can trigger or worsen the acute nerve symptoms.
- Oxaliplatin is prepared and given only by trained oncology staff.
Avoid Interactions
- Tell the oncology team about every medicine, herbal product and supplement being taken, since several interactions increase oxaliplatin's toxicity.
- Combining oxaliplatin with other drugs that prolong the heart's QT interval, including certain antiarrhythmic medicines, raises the risk of serious abnormal heart rhythms and should generally be avoided.
- Other medicines that can harm the kidneys should also be avoided where possible, because oxaliplatin is cleared through the kidneys and nephrotoxic combinations increase toxicity.
- Closer monitoring of blood clotting is needed with anticoagulants such as warfarin, since prolonged prothrombin time, elevated INR and bleeding have been reported with concurrent use.
- Oxaliplatin must be diluted only in 5% dextrose solution — never with sodium chloride or other chloride-containing fluids — and must not be mixed with any other medicine in the same infusion line.
References
Frequently Asked Questions
Oxaliplatin Injection is a platinum-based chemotherapy medicine used with fluorouracil and leucovorin. It treats stage III colon cancer after surgery and advanced colorectal cancer in adults. It is always given in combination, never alone, as part of an oncologist-supervised chemotherapy plan.
A hospital or clinic team gives oxaliplatin as an intravenous infusion over about 2 hours, usually every 2 weeks alongside leucovorin and fluorouracil. You do not take it by mouth or give it to yourself; only trained oncology staff prepare and administer it.
Oxaliplatin carries a boxed warning for severe, sometimes fatal allergic reactions, including anaphylaxis, which can happen within minutes of any infusion, at any cycle. Tell your nurse immediately about facial swelling, breathing trouble, rash, or chest tightness during or shortly after treatment.
Avoid ice, cold drinks, and cold air around infusion days, since cold can trigger or worsen nerve symptoms like numbness. Avoid pregnancy or breastfeeding during treatment, and tell your team about all other medicines, especially blood thinners and heart-rhythm drugs.
Your team checks liver function tests before treatment and before every cycle, along with blood counts, kidney function and nerve symptoms. The dose may be lowered if your kidneys are severely impaired. Report new numbness, tingling, or difficulty with fine movements right away.
No. Oxaliplatin can harm a developing baby, so effective contraception is required during treatment and for 9 months afterwards in women and 6 months afterwards in men. Breastfeeding should stop during treatment and for 3 months after the last dose.

Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.